Hongyu Zhang

Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study

Yu Wang, Xuejie Jiang, F. Huang, 2023, Journal of Internal Medicine.

Clinical and genetic characteristics predict outcomes of acute myeloid leukemia patients with FLT3 mutations receiving venetoclax‐based therapy

Hua Jin, Zhiqiang Sun, Guopan Yu, 2024, Cancer medicine.

Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2

Qiwen Deng, Zhiqiang Sun, Xinyou Zhang, 2023, Journal of Cancer Research and Therapeutics.

Homoharringtonine Overcomes the Negative Impact of Genetic Patterns on Venetoclax Plus Azacitidine Regimen in Relapsed/Refractory Acute Myeloid Leukemia: A Multi-Center, Cohort Study

Xuejie Jiang, L. Xuan, Hua Jin, 2023, Blood.